Bavituximab Antiviral PDF Print E-mail

Peregrine's PS targeting antibodies have the potential to address a common immune evasion mechanism exploited by infectious pathogens. Exposed PS is a subject of increasing study by researchers worldwide as a result of its thoroughly documented immunosuppressive activity, its active role in numerous infections, and its potential as a valid broad-spectrum therapeutic target.

Previous results from our PS-targeting infectious disease program include:

Publication in The Journal of Immunology Research demonstrating the ability of bavituximab to  bind to Ebola virions and Ebola virus-infected cells in vitro.

Publication in the Journal of Experimental Medicine demonstrating the ability of PS-targeting antibodies to inhibit HIV infection in vitro.

Data published in the journal Nature Medicine supporting broad-spectrum antiviral activity of PS targeting antibodies against lethal viral infections in animals.

Clinical stage Hepatitis C virus (HCV) program:

  • Randomized Phase II clinical trial evaluating our lead PS-targeting antibody bavituximab combined with ribavirin versus pegylated interferon alpha-2a with ribavirin in patients infected with genotype-1 HCV.
  • Three completed Phase I HCV clinical trials in which bavituximab was generally safe and well tolerated

Several U.S. and international issued patents and allowed applications establishing intellectual property leadership in the emerging field of PS targeting therapeutics for the treatment of life-threatening infections.